Monitoring of residual disease in chronic myelogenous leukemia: Methodological approaches and clinical aspects

Leukemia

Volumn 10, Issue 5, 1996, Pages 896-906

  Lion, T ^a  

^a CHILDREN'S CANCER RESEARCH INSTITUTE   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; DNA;

ALLOGENIC BONE MARROW TRANSPLANTATION; CANCER DIAGNOSIS; CHROMOSOME ANALYSIS; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; DIAGNOSTIC TEST; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; MINIMAL RESIDUAL DISEASE; PATIENT MONITORING; PHILADELPHIA 1 CHROMOSOME; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; SOUTHERN BLOTTING;

EID: 0029950176     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Opalka B, Wandl UB, Becher R, Kloke O, Nagel-Hiemke M, Moritz T, Beer U, Seeber S, Niederle N. Minimal residual disease in patients with chronic myelogenous leukemia undergoing longterm treatment with recombinant Interferon α-2b alone or in combination with interferon y. Blood 1991; 78: 2188-2193.
2. Freund M, Huber Ch. Interferon alpha has become a standard in the treatment of chronic myelogenous leukemia. Semin Hematol 1993; 30: 1-5. and Freund M, Hild A, Grote-Metke R, Nowak B, Otremba B, Wörmann B, Koch O, Dohmen M, Kleine HD, Link H, Hiddemann W, Hinrichs F, Balleisen L, Fonatsch C, Poliwoda H. Combination of chemotherapy and interferon a-2b in the treatment of chronic myelogenous leukemia. Semin Hematol 1993; 30: 11-13.
3. Freund M, Huber Ch. Interferon alpha has become a standard in the treatment of chronic myelogenous leukemia. Semin Hematol 1993; 30: 1-5. and Freund M, Hild A, Grote-Metke R, Nowak B, Otremba B, Wörmann B, Koch O, Dohmen M, Kleine HD, Link H, Hiddemann W, Hinrichs F, Balleisen L, Fonatsch C, Poliwoda H. Combination of chemotherapy and interferon a-2b in the treatment of chronic myelogenous leukemia. Semin Hematol 1993; 30: 11-13.
4. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon α-2a compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. New Engl J Med 1994; 330: 820-825.
5. Kantarjian H, Deisseroth A, Kurzrock R, Estrov Z, Talpaz M. Chronic myelogenous leukemia: a concise update. Blood 1993; 82: 691-703.
6. Talpaz M, Kantarjian H, Kurzrock R, Trujillo JM, Gutterman JU. Interferon-α produces sustained cytogenetic responses in chronic myelogenous leukemia. Ann Intern Med 1991; 114: 532-538.
7. Lee MS, Kantarjian H, Talpaz M, Freireich EJ, Deisseroth A, Trujillo JM, Stass S. Detection of minimal residual disease by polymerase chain reaction in Philadelphia chromosome-positive chronic myelogenous leukemia following interferon therapy. Blood 1992; 79: 1920-1923.
8. Mahon FX, Daheron L, Malinge MC, Ahmad M, Delfau MH, Grandchamp B, Kitzis A, Tanzer J, Guilhot F. Polymerase chain reaction detection of residual disease in chronic myelogenous leukemia patients in complete cytogenetic remission under interferon or without chemotherapy. Leukemia 1992; 6: 1232-1234.
9. Dhingra K, Kurzrock R, Kantarjian H. Minimal residual disease in interferon-treated chronic myelogenous leukemia: results and pitfalls of analysis based on polyrnerase chain reaction. Leukemia 1992; 6: 754-760.
10. Martial P, Maisin D, Philippe M, Ferrant A, Michaux JL, Cassiman JJ, Van den Berghe H, Sokal C. Detection of residual BCR/ABL transcripts in chronic myeloid leukaemia patients in complete remission using the polymerase chain reaction and nested primers. Br J Haematol 1990; 75: 355-358.
11. Bartram CR, Yokota S, Hansen-Hagge TE, Janssen JWG. Detection of minimal residual disease by polymerase chain reaction. Bone Marrow Transplant 1990; 6 (Suppl 1): 4-8.
12. Wandl UB, Bützler R, Niederle N, Kloke O, Mengelkoch B, Becher R, Seeber S, Opalka B. Bcr-abl-positive and -negative clonogenic cells in CML patients undergoing long-term interferon treatment. Leukemia 1994; 8: 776-779.
13. Lion T, Gaiger A, Henn T, Hörth E, Haas OA, Geissler K, Gadner H. Use of quantitative polymerase chain reaction to monitor residual disease in chronic myelogenous leukemia during treatment with interferon. Leukemia 1995; 9: 1353-1360.
14. Cross NCP, Hughes T, Feng L, O'Shea P, Bungey J, Marks DI, Ferrant A, Martiat P, Goldman JM. Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: correlations with acute graft-versushost disease and relapse. Br J Haematol 1993; 84: 67-74.
15. Lion T. Clinical implications of qualitative and quantitative polymerase chain reaction analysis in the monitoring of patients with chronic myelogenous leukemia. Bone Marrow Transplant 1994; 14: 505-509.
16. Lion T, Izraeli S, Henn T, Gaiger A, Mor W, Gadner H. Monitoring of residual disease in chronic myelogenous leukemia by quantitative polymerase chain reaction. Leukemia 1992; 6: 495-499.
17. Lion T, Henn T, Gaiger A, Kalhs P, Gadner H. Early detection of relapse after bone marrow transplantation in patients with chronic myelogenous leukaemia. Lancet 1993; 341: 275-276.
18. Cross NCP, Feng L, Chase A, Bungey J, Hughes T, Goldman JM. Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood 1993; 82: 1929-1936.
19. Westbrook CA. The role of molecular techniques in the clinical management of leukemia. Cancer 1992; 70: 1695-1700.
20. 1) translocation in chronic myelogenous leukemia. Leukemia 1988; 2: 648-657.
21. Griesshammer M, Hehlmann R, Hochhaus A, Talpaz M, Tura S, Stryckmans P, Allan NC, Tanzer J, Kolb HJ, Heimpel H. Interferon in chronic myeloid leukemia. Ann Hematol 1993; 67: 101-106.
22. Heisterkamp N, Stephenson JR, Groffen J, Hansen A, de Klein A, Bartram CR, Grosveld G. Localization of the c-abl oncogene adjacent to a translocation breakpoint in chronic myelocytic leukemia. Nature 1983; 306: 239-242.
23. Benn P, Soper I, Eisenberg A, Silver R, Coleman M, Cacciapaglia B, Bennet L, Baird M, Silverstein M, Berger C, Bernhardt B. Utility of molecular genetic analysis of bcr rearrangement in the diagnosis of chronic myeloid leukemia. Cancer Cenet Cytogenet 1987; 29: 1-7.
24. Grossman A, Silver RT, Szatrowski TP, Gutfriend A, Verma RS, Benn PA. Densitometric analysis of Southern blot autoradiographs and its application to monitoring patients with chronic myeloid leukemia. Leukemia 1991; 5: 540-544.
25. Lion T, Prischl F, Haas OA, Pont J, Schwarzmeier J. Non-radioactive detection of the rearranged BCR/ABL sequences amplified by polymerase chain reaction. Leukemia 1991; 5: 156-159.
26. Shtalrid M, Talpaz M, Kurzrock R, Kantarjian H, Trujillo J, Guttermann J, Yoffe G, Blick M. Analysis of breakpoints within the bcr gene and their correlation with the clinical course in Philadelphiapositive chronic myelogenous leukemia. Blood 1988; 72: 485-491.
27. Popenoe DW, Schaefer-Rego K, Mears JG, Bank A, Leibowitz D. Frequent and extensive deletion during the 9;22 translocation in CML. Blood 1986; 68: 1123-1128.
28. Lion T, Gaiger A, Henn T, Kalhs P, Gadner H. Early detection of incipient relapse and monitoring of treatment efficacy in patients with chronic myelogenous leukaemia by quantitative polymerase chain reaction. Ann Hematol 1993; 67 (Suppl 1): 299 (abstr.).
29. + cells arising from hematopoietic progenitors in chronic myeloid leukemia. Blood 1994; 83: 1744-1749.
30. Arnoldus EPJ, Wiegant J, Noordermeer IA, Wessels JW, Beverstock GC, Grosveld GC, van der Ploeg M, Raap AK. Detection of the Philadelphia chromosome in interphase nuclei. Cytogenet Cell Genet 1990; 54: 108-111.
31. Tkachuk DC, Westbrook CA, Andreeff M, Donlon TA, Cleary ML, Suryanarayan K, Homge M, Redner A, Gray J, Pinkel D. Detection of bcr-abl fusion in chronic myelogenous leukemia by in situ hybridization. Science 1990; 250: 559-562.
32. Lengauer C, Riethman HC, Speicher MR, Taniwaki M, Konecki D, Green ED, Becher R, Olson MV, Cremer T. Metaphase and interphase cytogenetics with Alu-PCR-amplified yeast artificial chromosome clones containing the BCR gene and the protooncogenes c-raf-1, c-fms, c-erb2. Cancer Res 1992; 52: 2590-2596.
33. Anastasi J, Le Beau MM, Vardiman JW, Fernald AA, Larson RA, Rowley JD. Detection of trisomy 12 in chronic lymphocytic leukemia by fluorescence in situ hybridization in interphase cells: a simple and sensitive method. Blood 1992; 79: 1796-1801.
34. Bentz M, Cabot C, Moos Marion, Speicher MR, Ganser A, Lichter P, Döhner H. Detection of chimeric BCR-ABL genes on bone marrow samples and blood smears in chronic myeloid and acute lymphoblastic leukemia by in situ hybridization. Blood 1994; 83: 1922-1928.
35. Delfau MH, Kerckaert JP, d'Hooghe MC, Fenaux P, Lai JC, Jouet JP, Grandchamp B. Detection of minimal residual disease in chronic myelogenous leukemia patients after bone marrow trans-plantation by polymerase chain reaction. Leukemia 1990; 4: 1-5.
36. Pignon JM, Henni T, Amselem S, Vidaud M, Duquesnoy P, Vernant JP, Kuentz M, Cordonnier C, Rochant H, Goossens M. Frequent detection of residual disease by use of the polymerase chain reaction in long-term survivors after bone marrow transplantation for chronic myeloid leukemia. Leukemia 1990; 4: 83-86.
37. Lion T, Izraeli S, Henn T, Gaiger A, Mor W, Gadner H. Monitoring of residual disease in chronic myelogenous leukemia by quantitative polymerase chain reaction. Leukemia 1992; 6: 495-499.
38. Lion T, Henn T, Gaiger A, Kalhs P, Gadner H. Early detection of relapse after bone marrow transplantation in patients with chronic myelogenous leukaemia. Lancet 1993; 341: 275-276.
39. Cross NCP, Feng L, Chase A, Bungey J, Hughes T, Goldman JM. Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood 1993; 82: 1929-1936.
40. Lin F, Goldman JM, Cross NCP. A comparison of the sensitivity of blood and bone marrow for the detection of minimal residual disease in chronic myeloid leukemia. Br J Haematol 1994; 86: 683-685.
41. van Rhee, Lin F, Cross NCP, Reid CDL, Lakhasi AKV, Szydlo RM, Goldman JM. Detection of residual leukaemia more than 10 years after allogeneic bone marrow transplantation for chronic myelogenous leukemia. Bone Marrow Transplant 1994; 14: 609-612.
42. Kolb HJ, Mittermüller J, Clemm Ch, Holler E, Ledderose G, Brehm C, Heim M, Wilmanns W. Donor lymphocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462-2465.
43. van Rhee F, Feng L, Cullis JO, Spencer A, Cross NCP, Chase A, Garicochea B, Bungey J, Barrett J, Goldman JM. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematological relapse. Blood 1994; 83: 3377-3383.
44. Gaiger A, Henn T, Hörth E, Geissler K, Mitterbauer G, Maier-Dobesberger T, Greinix H, Mannhalter C, Haas OA, Lechner K, Lion T. Increase of BCR-ABL chimeric mRNA expression in tumor cells of patients with chronic myelogenous leukemia precedes dis-ease progression. Blood 1995; 86: 2371-2378.